Status:
COMPLETED
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Lead Sponsor:
The Cleveland Clinic
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Leukemia
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, cytarabine, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from ...
Detailed Description
OBJECTIVES: * Determine the complete remission rate in patients with acute myelogenous leukemia treated with induction chemotherapy comprising mitoxantrone hydrochloride, cytarabine, and etoposide. *...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia
- Previously untreated disease
- Previous hydroxyurea and/or corticosteroids are acceptable
- No preexisting history of a hematologic disorder
- Myelodysplastic features allowed
- No acute leukemia secondary to previous therapy
- No leukemic meningitis
- PATIENT CHARACTERISTICS:
- Bilirubin \< 2.0 mg/dL (unless felt to be increased because of hepatic infiltration with leukemia)
- Creatinine \< 2.0 mg/dL
- Pregnant or lactating patients are ineligible
- Fertile patients must use effective contraception
- No history of or active congestive heart failure
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00274807
Start Date
June 1 2001
End Date
May 1 2008
Last Update
February 11 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.